

## Review Article

Indian J Med Res 133, February 2011, pp 179-187

# Cholera toxin: A paradigm of a multifunctional protein

Kaushik Bharati & Nirmal K. Ganguly

*National Institute of Immunology, New Delhi, India*

Received June 14, 2010

**Cholera toxin (CT) was discovered exactly half a century ago by S.N. De. We have come a long way since this epoch-making discovery. Retrospectively, science had to wait a long time since Koch's prediction of the existence of a toxin, and its actual discovery by De. CT is not just another enterotoxin that causes the signs and symptoms of the dreaded disease, cholera. It is unique in many respects, starting from its structure to its functions. CT is a multifunctional protein that is capable of influencing the immune system in many ways. It not only has remarkable adjuvant properties, but also acts as an anti-inflammatory agent, by modulating specific signal transduction pathways. Its immunomodulatory properties can be harnessed for treatment of various autoimmune disorders, and have shown great promise in the area of immunotherapeutics. CT can truly be considered as a paradigm of a multifunctional protein.**

**Key words** Adjuvant - cholera toxin - immunomodulation - immunotherapy

### Cholera toxin: an historical introduction

Cholera toxin (CT) is produced by *Vibrio cholerae*. As in most discoveries, a long chain of events led up to the final discovery of CT<sup>1</sup>. *V. cholerae* was isolated in pure culture from a stool sample originated in Egypt by Robert Koch in 1884<sup>2</sup>. The existence of CT was first postulated by Koch in 1886. He opined that the symptoms caused by *V. cholerae* were due to a "poison" that was secreted by the organism. However, the discovery of CT had to wait for more than half-a-century when S.N. De, in 1959, reported that cell-free *V. cholerae* culture filtrate was capable of eliciting massive accumulation of "rice-water" fluid in the ligated ileal loops of adult rabbits<sup>3</sup>, unequivocally demonstrating the existence of a toxin. The same year, from the Haffkine Institute in Mumbai (then Bombay), Dutta and colleagues described the production of diarrhoea in infant rabbits by a crude protein isolate

from *V. cholerae* culture filtrate<sup>4</sup>, thereby strengthening De's observations.

Richard Finkelstein's group, over the following decade, subsequently isolated and purified CT<sup>5-7</sup>. Following purification, two factors were identified that possessed differing biological activities<sup>6</sup> viz., the active principle, the holotoxin (AB<sub>5</sub>), which was termed as "cholera toxin"; and the B<sub>5</sub> oligomer, termed as "cholera toxin B", as it was not itself toxic, but contributed to elicit the symptoms of cholera. The heterogeneous subunit structure of CT was subsequently unequivocally demonstrated by means of biochemical techniques<sup>8</sup>. We now know, in intimate detail, how the CT subunits function.

The next major development was the discovery of the CT receptor by King and van Heyningen in 1973<sup>9</sup>. They observed that the monosialoganglioside GM1:

[{Gal(β1-3)GalNac(β1-4)(NeuA-c(α2-3)Gal(β1-4)Glc}-ceramide] prevented CT from increasing the capillary permeability of rabbit skin, prevented CT from inducing accumulation of rice-water-like fluid in ligated rabbit ileal loops, and also inhibited the action of CT on the adenylate cyclase (AC) system in the guinea pig small intestine.

Following these landmark discoveries, many unique functions of CT were discovered that would pave the way towards finding suitable medical applications. This review will address the issue of the multi-functionality of this remarkable protein.

### **Cholera toxin: from structure to function**


CT is made up of two types of subunits. The larger A subunit (240 amino acids; MW 28 kD) is located centrally, while the five B subunits (103 amino acids; MW 11 kD each; aggregate MW ~56 kD) are located peripherally. The A subunit of CT has over 82 per cent sequence identity with the *Escherichia coli* heat-labile enterotoxin (LT), while the B subunits of the former shares over 83 per cent sequence identity with the latter<sup>10</sup>. The elucidation of the three-dimensional structure of CT was a major achievement to enhance our understanding of this remarkable toxin<sup>11,12</sup>. The three-dimensional structure of CT further corroborated the sequence data that it shared a similar structure to LT, the crystal structure of which had been determined a few years earlier<sup>13,14</sup>. The A subunit consists of two domains (A1 and A2). In both the toxins, the upper A1 domain of the wedge-shaped A subunit is held above the plane of the doughnut-shaped pentameric B subunits by the tethering A2 domain, which in case of CT, is an alpha helix for almost its entire length. The carboxy-terminal of the A2 passes through the opening created by the doughnut arrangement of the B subunits. The four carboxy-terminal residues of the A2 chain are Lys-Asp-Glu-Leu (K-D-E-L).

Cholera toxin, by acting as a classical A-B type toxin, leads to ADP-ribosylation of G protein, and constitutive activation of AC, thereby giving rise to increased levels of cyclic AMP within the host cell (Fig. 1). As a result, electrolyte imbalance occurs due to a rapid efflux of chloride ions by the cystic fibrosis transmembrane conductance regulator (CFTR), decreased influx of sodium ions, leading to massive water efflux through the intestinal cells, thereby causing severe diarrhoea and vomiting, the cardinal clinical signs of cholera. Diarrhoea, if untreated, leads to severe dehydration, electrolyte abnormalities and metabolic acidosis<sup>15</sup>, almost inevitably resulting in death.

The toxic action of CT is initiated by binding of its B subunits to the high-affinity monosialoganglioside GM1 receptors. Each B subunit monomer has a binding site for GM1. Moreover, a single amino acid from a neighbouring B subunit also plays an important role in binding<sup>16</sup>, explaining the much higher binding affinity of the CTB pentamer, as compared to that of the CTB monomer. Endocytosis of CT may follow one of three pathways: (i) lipid raft/caveolae mediated endocytic pathway, (ii) clathrin mediated endocytic pathway, or (iii) ADP-ribosylation factor 6 (Arf6)-associated endocytic pathway. CT then travels to the endoplasmic reticulum (ER) in a retrograde fashion. After reaching the ER, the A subunit of CT (CTA) dissociates from its B subunit (CTB). Earlier studies indicated that a functional Golgi apparatus was essential<sup>17</sup> in this transportation pathway, but later studies showed that the Golgi system was not mandatory<sup>18</sup>. It was initially thought that the KDEL signal, present at the carboxy-terminal of CTA2, which is a classical eukaryotic signal for ER retention, was essential for retrograde trafficking. However, mutagenesis and blocking studies have indicated that this signal is not essential for retrograde transport, but rather, serves for the retrieval of the dissociated CTA from the Golgi apparatus to the ER<sup>17,18</sup>. This observation has been strengthened by the fact that CTB, which does not possess a KDEL signal, is also transported to the ER in a retrograde fashion<sup>19</sup>. The ADP ribosylation activity of CT resides in CTA1. Hence, entry of CTA1 into the cytosol is a crucial step in the intoxication process. This involves the ER-associated degradation pathway, or degradasome, the function of which is to retrieve misfolded proteins from the ER for their degradation in the cytosol. CTA1 escapes degradation in spite of passing through the degradasome, presumably because of its low lysine content, an essential marker for ubiquitination<sup>20</sup>. During transport through the degradasome CTA1 unfolds and refolds, which involves reduction by protein disulphide isomerase and reoxidation by Ero1<sup>21</sup>. CTA1, upon entry into the cytosol, catalyzes the ADP-ribosylation of the trimeric G $\alpha$  component of AC (Fig. 1). This leads AC to remain in its GTP-bound state, resulting in enhanced AC activity and increased intracellular cAMP concentrations. High levels of cAMP start a cascade that eventually lead to the severe clinical manifestations of cholera, as has been highlighted above.

### **WO7: a novel cholera toxin**

During an outbreak of cholera in Warangal, Andhra Pradesh, *V. cholerae* WO7 (serogroup O1) strain was



**Fig. 1.** ADP-ribosylation. The 22kD A1 domain of CT (CTA1) catalyzes the transfer of the ADP-ribose moiety of NAD<sup>+</sup> to an Arginine residue (Arg<sup>201</sup>) of the  $\alpha$  subunit of Gs, leading to defective regulation of adenylyl cyclase and overproduction cAMP.

isolated from patients with diarrhoea. The interesting point about this strain was the fact that it produced an extracellular toxin (WO7) despite the absence of *ctx*, *zot*, and *ace* genes from its genome. The purified WO7 toxin caused fluid accumulation in ligated rabbit ileal loops, elongation of Chinese hamster ovary cells, rounding of Vero cells and agglutination of freshly isolated rabbit erythrocytes. The purified toxin was highly specific for antisera raised in rabbits against the purified toxin, as revealed by immunodiffusion and immunoblot assays. However, the toxin did not cross-react with either CT or LT, in these systems. The WO7 toxin agglutinated GM1-coated erythrocytes, indicating that GM1 could be its receptor. The enterotoxic activity of the WO7 toxin was found to be 10-fold greater than that of CT, but could be neutralized by antisera raised in rabbits against the purified toxin<sup>22</sup>. A model was subsequently proposed to explain the mode of action of the WO7 toxin at the intracellular level, implicating Ca<sup>2+</sup>, cAMP, inositol triphosphate and protein kinase C in playing critical roles<sup>23</sup>. It was also found that upon WO7-toxin stimulation of enterocytes, an increase in the level of reactive oxygen species was noted, that correlated with a simultaneous decrease in the levels of antioxidants such as catalase and superoxide dismutase. The levels of reactive nitrogen intermediates were also found to be high in WO7-toxin treated enterocytes, indicating that the toxin played a role in altering mucosal permeability. It was concluded that significant increase in the levels of second messengers, coupled with a decrease in antioxidant defenses were key factors in mediating the enterotoxic action of the toxin. The ability of serogroup O1 strain *V. cholerae* WO7 to produce a toxin 10 times

more potent than CT, in spite of the absence of *ctx*, *zot* and *ace* genes, is a cause for concern and the foregoing findings warrant further in-depth studies of this strain.

#### Adjuvant action of cholera toxin

That CT possessed adjuvant activity, was first reported in the early seventies<sup>24</sup>. Injection of sheep red blood cells (SRBCs) with CT into mice resulted in a 13-fold increase in the levels of systemic anti-SRBC antibody titres. Moreover, transcutaneous immunization was made possible by simply mixing CT with various antigens, such as tetanus toxoid, diphtheria toxoid or bovine serum albumin (BSA) and applying on the skin of mice<sup>25</sup>. The adjuvant activity of CT may be attributed to the enhanced antigen presentation by various types of antigen presenting cells (APCs), such as macrophages, dendritic cells (DCs) and B cells. In B cells, both recombinant CT (rCT) and recombinant CTB (rCTB) promote isotype differentiation that leads to increased IgA formation. It has been suggested that both enzymatic activity and receptor binding contribute to the stimulatory effects of the toxin<sup>26</sup>. CT has also been reported to upregulate various cell surface molecules such as co-stimulatory molecules and chemokine receptors in murine and human DCs as well as in other APCs<sup>27,28</sup>. CT also stimulates the secretion of IL-1 from macrophages, which enhances their APC function<sup>29</sup>. IL-1 itself is also an efficient mucosal adjuvant. The polarity of the immune response generated by CT is a matter of debate. While some studies indicate that CT-treated DCs prime naïve T cells *in vitro* and drive them towards a Th2 phenotype<sup>30</sup>, others have reported the toxin to induce a mixed Th1/Th2 type of immune

response<sup>28</sup>. In contrast to its stimulatory effect on B cells and APCs, rCTB induces apoptosis of CD8+ T cells<sup>31</sup>. Importantly, depletion of CD8+ T cells by rCTB has been observed *in vivo*<sup>32</sup>.

CT strongly potentiates the immunogenicity of most antigens, whether these are linked to or simply admixed with the toxin, provided that the antigen is given at the same time and at the same mucosal surface as the toxin. There are various antigens towards which CT exhibits adjuvant activity (Table I)<sup>33-47</sup>.

### **Development of non-toxic derivatives of CT as mucosal adjuvants**

Although animal studies were highly impressive, it soon became evident that the CT holotoxin was much

too toxic for use in humans. Hence, to circumvent the toxicity problems associated with the holotoxin, efforts were directed towards developing non-toxic recombinant derivatives of CT. CTB was an obvious choice as an adjuvant, as it was non-toxic. However, CTB proved to be a much poorer adjuvant than its holotoxin counterpart. Coupling the antigens to CTB increased the immunogenicity appreciably as it facilitated receptor-mediated uptake and subsequent presentation by the APCs. Some examples of antigens expressed as CTB fusions are given in Table II<sup>48-50</sup>.

Site-directed mutagenesis was one approach to generate CT mutants with reduced toxicity but retaining significant adjuvanticity. Initial studies indicated that if the ADP-ribosylating activity (the toxic property of CT) was absent in the mutant derivatives, the adjuvant function was also lost<sup>51</sup>. However, subsequent studies indicated that the ADP-ribosyltransferase activity was not essential for the adjuvant function, and that separation of this toxic component in many instances did not hamper the adjuvanticity appreciably<sup>52</sup>. Some examples of non-ADP-ribosylating mutants exhibiting immunogenic and adjuvant activity are given in Table III<sup>53-55</sup>. Partial blocking of the ADP-ribosylation site can be achieved by adding peptides to the amino terminal of CTA1 that produces steric hindrance on the enzymatically active site, thereby reducing the toxicity<sup>56</sup>. In yet another strategy, CTA1 was linked to a cell-binding domain, having affinity for APCs, derived from *Staphylococcus aureus* protein A (CTA1-DD). This hybrid specifically targets the B cells and has been found to work well when administered intranasally, but not so well when administered orally. This limitation has been overcome by fusing CTA1-DD to immune-stimulating complexes. Oral immunization with the CTA1-DD-ISCOM fusion complex generated both systemic and mucosal responses with Th1/Th2 bipolarity<sup>57</sup>. Synthetic oligodeoxynucleotides (ODNs) containing unmethylated 'CpG' motifs have been successfully employed as systemic adjuvants and represent a promising mucosal adjuvant. Linking CpG ODNs to CTB (CpG ODN-CTB conjugate) represents a novel strategy that is capable of activating APCs *in vitro* and stimulating both T cell and antibody responses *in vivo*<sup>58</sup>.

### **Cholera toxin and immunomodulation**

In addition to its adjuvant properties, CT has been recognized as a potent immunomodulator. The immunomodulatory function of CT can be attributed to three basic properties of the toxin itself: (i) ability

**Table I.** Antigens towards which CT or its subunits have adjuvant activity

Antigen	Route	Reference
Keyhole Limpet Haemocyanin (KLH)	peroral (p.o.)	33,34
	intranasal (i.n.)	
	intravenous (i.v.)	35
Ovalbumin (OVA)	i.n.	35
	i.v.	
Antigen I/II (AgI/II) from <i>Streptococcus mutans</i>	p.o.	36
Influenza virus	p.o.	37
<i>Pseudomonas aeruginosa</i> polysaccharide	p.o.	38
Sendai virus	p.o.	39
	i.n.	
	subcutaneous (s.c.)	
Tetanus toxoid (TT)	p.o.	40
Killed <i>Campylobacter</i>	p.o.	41
<i>Toxoplasma gondii</i> sonicate (Tso)	p.o.	42
Respiratory syncytial virus glycoprotein F (RSV gF)	i.n.	43
<i>Helicobacter pylori</i> recombinant Urease ( <i>H. pylori</i> rUrease)	p.o.	44
Soluble worm antigen preparation (SWAP) from <i>Schistosoma mansoni</i>	intradermal (i.d.)	45
<i>T. gondii</i> surface antigen 1 (SAG1)	i.n.	46
Pneumococcal surface protein A (PspA) from <i>Streptococcus pneumoniae</i>	p.o.	47



**Table II.** Some foreign antigens expressed as CTB fusions

Antigen	Immunogenicity	Reference
HIV-1 envelope protein gp120	Serum anti-gp120 IgG (in mice)	48
A decapeptide highly homologous to the heat-stable enterotoxin of <i>E. coli</i> (STa)	Serum anti-STa IgG (in rabbits)	49
Serine-rich <i>Entamoeba histolytica</i> protein (SREHP)	Serum anti-SREHP IgG, IgA; stool and bile IgA (in mice)	50

**Table III.** Immunogenicity and adjuvant activity of some non-ADP-ribosylating CT mutants

Antigen	Mutation	Animal (route)	Enzymatic and biological activity	Immunogenicity (antibody type)	Adjuvant activity	Reference
OVA	E112K S61F	Mice (s.c.)	–	+ (IgG; IgE)	+	53
OVA, TT, Influenza virus	S61F	Mice (i.n.)	–	+ (IgG; IgA)	+	54
OVA, Fragment C of TT	S63K P106S	Mice (i.n.)	– ±	± (IgG; IgA) (negligible) ± (IgG; IgA)	± (negligible) ±	55

E112K=Glu to Lys at position 112; S61F=Ser to Phe at position 61; S63K=Ser to Lys at position 63; P106S=Pro to Ser at position 106


to act as a true enterotoxin by exhibiting stability in the harsh enteric environment, (ii) ability to bind, via the B subunits, to specific GM1 ganglioside receptors present in the gut mucosa as well as APCs, thereby facilitating antigen uptake and presentation, and (iii) inherent immunomodulatory properties of the toxin itself.

*V. cholerae* activates the innate immune response through its lipopolysaccharide (LPS) binding to Toll-like receptor 4 present on the surface of APCs such as macrophages, leading to the release of proinflammatory cytokines like TNF $\alpha$  by activation of a signal transduction cascade. However, prior treatment of macrophages with CTX suppresses TNF $\alpha$  production in response to LPS, by up to 80 per cent. Since nitric oxide (NO) synthesis requires signaling by TNF $\alpha$ , CT treatment simultaneously reduces the production of NO<sup>59</sup>. Importantly, it has been found that similar effects can be produced by the CTB alone<sup>60</sup>, indicating that the immunomodulatory activity might reside in CTB and do not require the catalytically active A subunit for this function. The underlying mechanism by which CTB exerts its immunomodulatory action has been dissected out by studies involving the mitogen activated protein kinase (MAPK) signal transduction pathway. It has been found that CTB induces MAPK phosphatase-1

(MKP1) expression and significantly inhibits Janus kinase and p38 activation, thereby leading to a substantial attenuation of TNF $\alpha$  and IL-6 production by LPS-stimulated macrophages<sup>61</sup>. It has been suggested that induction of MPK1 expression could be a potential underlying mechanism for the immunomodulatory action of CTB (Fig. 2).

### Cholera toxin B subunit for mucosal tolerization and immunotherapy

CT is capable of inducing mucosal immunological tolerance. Initial experiments revealed that when mice were fed with CTB-conjugated SRBC, there was an abrogation in the delayed-type hypersensitivity and IgE antibody responses upon systemic immunization with SRBCs<sup>62</sup>. Subsequent studies revealed that the ability of CTB to suppress inflammatory responses in an antigen-specific manner could hold potential for treatment of autoimmune diseases. Animal models of various autoimmune diseases were used in these studies. Thus, CTB conjugated to myelin basic protein was shown to prevent the development of experimental allergic encephalomyelitis, the rat equivalent of multiple sclerosis that affects humans<sup>63</sup>. Moreover, a CTB-insulin conjugate delayed the onset of insulin dependent diabetes mellitus in nitric oxide deficient mice<sup>64</sup>. More importantly,



**Fig. 2.** Molecular basis of immunomodulation by CTB. MKP1 expression plays a central role in immunomodulation by immunomodulatory agents like CTB. Extracellular inflammatory insult activates MAPK, p38 and JNK pathways, leading to generation of proinflammatory cytokines, resulting in an inflammatory response. Proinflammatory cytokines have an inhibitory effect on MKP1, which leads to further activation of the inflammatory response pathway (left side of diagram). CTB, as well as other anti-inflammatory agents augment MKP1 expression, which leads to inhibition of the pro-inflammatory cascade, thereby attenuating the inflammatory response (right side of diagram). MAPK: mitogen-activated protein kinase; MKP1: MAPK phosphatase-1; JNK: JUN N-terminal kinase.

unconjugated rCTB has also been found to induce long-lasting protection from diabetes in NOD mice<sup>65</sup>. Investigation of the mechanism of oral tolerization by CTB has revealed that, besides increasing the uptake of antigen across the mucosal barrier and presentation by APCs, regulatory T cells play a prominent role in the process<sup>66</sup>.

One of the major success stories of oral tolerance induction with CTB-antigen conjugates relates to the work on Behcet's disease (BD). BD is a multi-system inflammatory disorder with uveitis being a major complication. Following the identification of a BD-specific peptide (p336-351) within the human 60kD heat-shock protein, it was found that oral tolerization could be induced in Lewis rats by linking the peptide to rCTB, effectively reducing the incidence of uveitis from 65.8 to 16.7 per cent<sup>67</sup>. This study was followed by a phase I/II clinical trial in a selected number of patients. Oral tolerization with the BD-peptide-rCTB conjugate was attempted in patients with BD for preventing relapses of uveitis. The conjugate was administered thrice-weekly for 12 to 16 wk, which

allowed withdrawal of all immunosuppressive drugs in 5 of the 8 patients or 5 of 6 patients (who were free of disease activity prior to tolerization) without a relapse of uveitis. The clinical manifestations were correlated with immunological findings<sup>68</sup>. The positive findings of the preceding study have possibly fuelled a recent clinical trial in 15 patients suffering from Crohn's disease to address the issues of safety and short-term efficacy of rCTB in this particular autoimmune condition. Treatment with rCTB was found to be safe and well tolerated, with approximately 40 per cent of patients responding to treatment<sup>69</sup>.

### Cholera toxin B subunit for cholera vaccine development

Enteric infections accompanied by diarrhoea are a leading public health problem, particularly in the developing countries. Enterotoxin-producing bacteria are a leading cause of diarrhoea, of which *V. cholerae* accounts for the most severe disease, often in the form of epidemics. Most probably, the greatest contribution towards alleviating this age-old disease is the incorporation of rCTB itself in the vaccine preparation. Of the internationally licensed oral cholera vaccines, the most widely used vaccine, DUKORAL™ (SBL Vaccines, Sweden), consists of a mixture rCTB and heat or formalin-inactivated *V. cholerae* O1 whole cells of different serotypes and biotypes. This vaccine has been shown to be safe and effective in large-scale clinical trials.

### Conclusion

CT is a multifunctional protein that is truly remarkable in many respects. CT was initially thought to be just another enterotoxic protein that caused the life-threatening symptoms of cholera but further research revealed that this toxin possessed many unique features. Besides its unique structure, mode of intracellular trafficking, and ADP-ribosyltransferase activity, the toxin possesses a multifaceted character with regard to functionality. The major contribution of this unique toxin has been in the field of Immunology functioning as an effective adjuvant or an immunomodulator and holding promise in the area of therapeutics against various types of autoimmune diseases. Moreover, this toxin has a remarkable property for downregulating inflammatory reactions and the molecular mechanisms of its action could open avenues towards development and design of new anti-inflammatory agents for modulating various immune disorders in the foreseeable future.

## References

1. Pacini F. Osservazioni microscopiche e deduzioni patologiche sul colera asiatico. *Gazzetta Medica Italiana Federativa* 1854.
2. Koch R. An address on cholera and its bacillus. *Dtsch Med Wochenschr* 1884; 10: 111. (English translation in: *Br Med J* 1884; ii : 403-7, 453-9).
3. De SN. Enterotoxicity of bacteria-free culture filtrate of *Vibrio cholerae*. *Nature* 1959; 183 : 1533-4.
4. Dutta NK, Panse MV, Kulkarni DR. Role of cholera a toxin in experimental cholera. *J Bacteriol* 1959; 78 : 594-5.
5. Finkelstein RA, Norris HT, Dutta NK. Pathogenesis experimental cholera in infant rabbits. I. Observations on the intrainestinal infection and experimental cholera produced with cell-free products. *J Infect Dis* 1964; 114 : 203-16.
6. Finkelstein RA, LoSpalluto JJ. Pathogenesis experimental cholera: preparation and isolation of cholera toxin and cholera toxin. *J Exp Med* 1969; 130 : 185-202.
7. Finkelstein RA, LoSpalluto JJ. Production of highly purified cholera toxin and cholera toxin. *J Infect Dis* 1970; 121 (Suppl): S63-S72.
8. Lonngren I, Holmgren J. Subunit structure of cholera toxin. *J Gen Microbiol* 1973; 76 : 417-27.
9. King CA, Van Heyningen WE. Deactivation of cholera toxin by a sialidase monosialosylganglioside. *J Infect Dis* 1973; 127 : 639-47.
10. Dallas WS, Falkow S. Amino acid sequence homology between cholera toxin and *Escherichia coli* heat-labile toxin. *Nature* 1980; 288 : 499-501.
11. Zhang RG, Scott DL, Westbrook ML, Nance S, Spangler BD, Shipley GG, et al. The three-dimensional crystal structure of cholera toxin. *J Mol Biol* 1995; 251 : 563-73.
12. Zhang RG, Westbrook ML, Westbrook EM, Scott DL, Otwinowski Z, Maulik PR, et al. The 2.4 Å crystal structure of cholera toxin B subunit pentamer: cholera toxin. *J Mol Biol* 1995; 251 : 550-62.
13. Sixma TK, Pronk SE, Kalk KH, Wartna ES, van Zanten BA, Witholt B, et al. Crystal structure of a cholera toxin-related heat-labile enterotoxin from *E. coli*. *Nature* 1991; 351 : 371-7.
14. Sixma TK, Kalk KH, Van Zanten BA, Dauter Z, Kingma J, Witholt B, et al. Refined structure of *Escherichia coli* heat-labile enterotoxin, a close relative of cholera toxin. *J Mol Biol* 1993; 230 : 890-918.
15. Kaper JB, Morris JG Jr, Levine MM. Cholera. *Clin Microbiol Rev* 1995; 8 : 48-86.
16. Merritt EA, Sarfaty S, van den Akker F, L'Hoir C, Martial JA, Hol WG. Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. *Protein Sci* 1994; 3 : 166-75.
17. Majoul IV, Bastiaens PI, Soling HD. Transport of an external Lys-Asp-Glu-Leu (KDEL) protein from the plasma membrane to the endoplasmic reticulum: studies with cholera toxin in Vero cells. *J Cell Biol* 1996; 133 : 777-89.
18. Feng Y, Jadhav AP, Rodighiero C, Fujinaga Y, Kirchhausen T, Lencer WI. Retrograde transport of cholera toxin from the plasma membrane to the endoplasmic reticulum requires the trans-Golgi network but not the Golgi apparatus in Exo2-treated cells. *EMBO Rep* 2004; 5 : 596-601.
19. Fujinaga Y, Wolf AA, Rodighiero C, Wheeler H, Tsai B, Allen L, et al. Gangliosides that associate with lipid rafts mediate transport of cholera and related toxins from the plasma membrane to endoplasmic reticulum. *Mol Biol Cell* 2003; 14 : 4783-93.
20. Hazes B, Read RJ. Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. *Biochemistry* 1997; 36 : 11051-4.
21. Tsai B, Rapoport TA. Unfolded cholera toxin is transferred to the ER membrane and released from protein disulfide isomerase upon oxidation by Ero1. *J Cell Biol* 2002; 159 : 207-16.
22. Walia K, Ghosh S, Singh H, Nair GB, Ghosh A, Sahni G, et al. Purification and characterization of novel toxin produced by *Vibrio cholerae* O1. *Infect Immun* 1999; 67 : 5215-22.
23. Bhattacharyya S, Ghosh S, Shant J, Ganguly NK, Majumdar S. Role of the WO7-toxin on *Vibrio cholerae*-induced diarrhoea. *Biochim Biophys Acta* 2004; 1670 : 69-80.
24. Northrup RS, Fauci AS. Adjuvant effect of cholera enterotoxin on the immune response of the mouse to sheep red blood cells. *J Infect Dis* 1972; 125 : 672-3.
25. Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. *Nature* 1998; 391 : 851.
26. Lycke NY. Cholera toxin promotes B cell isotype switching by two different mechanisms. cAMP induction augments germ-line Ig H-chain RNA transcripts whereas membrane ganglioside GM1-receptor binding enhances later events in differentiation. *J Immunol* 1993; 150 : 4810-21.
27. Gagliardi MC, De Magistris MT. Maturation of human dendritic cells induced by the adjuvant cholera toxin: role of cAMP on chemokine receptor expression. *Vaccine* 2003; 21 : 856-61.
28. Eriksson K, Fredriksson M, Nordström I, Holmgren J. Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development. *Infect Immun* 2003; 71 : 1740-7.
29. Bromander A, Holmgren J, Lycke N. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages *in vitro*. *J Immunol* 1991; 146 : 2908-14.
30. Gagliardi MC, Sallusto F, Marinaro M, Langenkamp A, Lanzavecchia A, De Magistris MT. Cholera toxin induces maturation of human dendritic cells and licenses them for Th2 priming. *Eur J Immunol* 2000; 30 : 2394-403.
31. Yankelevich B, Soldatenkov VA, Hodgson J, Polotsky AJ, Creswell K, Mazumder A. Differential induction of programmed cell death in CD8+ and CD4+ T cells by the B subunit of cholera toxin. *Cell Immunol* 1996; 168 : 229-34.
32. Elson CO, Holland SP, Dertzbaugh MT, Cuff CF, Anderson AO. Morphologic and functional alterations of mucosal T cells by cholera toxin and its B subunit. *J Immunol* 1995; 154 : 1032-40.
33. Elson CO, Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. *J Immunol* 1984; 132 : 2736-41.

34. Lycke N, Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. *Immunology* 1986; 59 : 301-8.
35. Ågren LC, Ekman L, Löwenadler B, Lycke NY. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. *J Immunol* 1997; 158 : 3936-46.
36. Czerkinsky C, Russell MW, Lycke N, Lindblad M, Holmgren J. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. *Infect Immun* 1989; 57 : 1072-7.
37. Chen KS, Strober W. Cholera holotoxin and its B subunit enhance Peyer's patch B cell responses induced by orally administered influenza virus: disproportionate cholera toxin enhancement of the IgA B cell response. *Eur J Immunol* 1990; 20 : 433-6.
38. Abraham E, Robinson A. Oral immunization with bacterial polysaccharide and adjuvant enhances antigen-specific pulmonary secretory antibody response and resistance to pneumonia. *Vaccine* 1991; 9 : 757-64.
39. Liang XP, Lamm ME, Nedrud JG. Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus. *J Immunol* 1988; 141 : 1495-501.
40. Jackson RJ, Fujihashi K, Xu-Amano J, Kiyono H, Elson CO, McGhee JR. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. *Infect Immun* 1993; 61 : 4272-9.
41. Rollwagen FM, Pacheco ND, Clemens JD, Pavlovskis O, Rollins DM, Walker RI. Killed *Campylobacter* elicits immune response and protection when administered with an oral adjuvant. *Vaccine* 1993; 11 : 1316-20.
42. Bourguin I, Chardès T, Bout D. Oral immunization with *Toxoplasma gondii* antigens in association with cholera toxin induces enhanced protective and cell-mediated immunity in C57BL/6 mice. *Infect Immun* 1993; 61 : 2082-8.
43. Walsh EE. Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice. *Vaccine* 1993; 11 : 1135-8.
44. Pappo J, Thomas WD Jr, Kabok Z, Taylor NS, Murphy JC, Fox JG. Effect of oral immunization with recombinant urease on murine *Helicobacter felis* gastritis. *Infect Immun* 1995; 63 : 1246-52.
45. Akhiani AA, Nilsson LA, Ouchterlony O. Effect of cholera toxin on vaccine-induced immunity and infection in murine schistosomiasis mansonii. *Infect Immun* 1993; 61 : 4919-24.
46. Debard N, Buzoni-Gatel D, Bout D. Intranasal immunization with SAG1 protein of *Toxoplasma gondii* in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. *Infect Immun* 1996; 64 : 2158-66.
47. Yamamoto M, McDaniel LS, Kawabata K, Briles DE, Jackson RJ, McGhee JR, et al. Oral immunization with PspA elicits protective humoral immunity against *Streptococcus pneumoniae* infection. *Infect Immun* 1997; 65 : 640-4.
48. Bäckström M, Lebens M, Schödel F, Holmgren J. Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit. *Gene* 1994; 149 : 211-7.
49. Sanchez J, Svennerholm AM, Holmgren J. Genetic fusion of a non-toxic heat-stable enterotoxin-related decapeptide antigen to cholera toxin B-subunit. *FEBS Lett* 1988; 241 : 110-4.
50. Ryan ET, Butterson JR, Zhang T, Baker MA, Stanley SL Jr, Calderwood SB. Oral immunization with attenuated vaccine strains of *Vibrio cholerae* expressing a dodecapeptide repeat of the serine-rich *Entamoeba histolytica* protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-*V. cholerae* antibody responses in mice. *Infect Immun* 1997; 65 : 3118-25.
51. Lycke N, Tsuji T, Holmgren J. The adjuvant effect of *Vibrio cholerae* and *Escherichia coli* heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. *Eur J Immunol* 1992; 22 : 2277-81.
52. Giuliani MM, Del Giudice G, Giannelli V, Dougan G, Douce G, Rappuoli R, et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of *Escherichia coli* heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. *J Exp Med* 1998; 187 : 1123-32.
53. Yamamoto S, Takeda Y, Yamamoto M, Kurazono H, Imaoka K, Yamamoto M, et al. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. *J Exp Med* 1997; 185 : 1203-10.
54. Yamamoto S, Kiyono H, Yamamoto M, Imaoka K, Fujihashi K, Van Ginkel FW, et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. *Proc Natl Acad Sci USA* 1997; 94 : 5267-72.
55. Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. *Infect Immun* 1997; 65 : 2821-8.
56. Sanchez J, Wallerstrom G, Fredriksson M, Angstrom J, Holmgren J. Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (Sta-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccination. *J Biol Chem* 2002; 277 : 33369-77.
57. Mowat AM, Donachie AM, Jägewall S, Schön K, Löwenadler B, Dalsgaard K, et al. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen. *J Immunol* 2001; 167 : 3398-405.
58. Adamsson J, Lindblad M, Lundqvist A, Kelly D, Holmgren J, Harandi AM. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin. *J Immunol* 2006; 176 : 4902-13.
59. Cong Y, Oliver AO, Elson CO. Effects of cholera toxin on macrophage production of co-stimulatory cytokines. *Eur J Immunol* 2001; 31 : 64-71.
60. Burkart V, Kim Y-E, Hartmann B, Ghiea I, Syldath U, Kauer M, et al. Cholera toxin B pretreatment of macrophages and monocytes diminishes their proinflammatory responsiveness to lipopolysaccharide. *J Immunol* 2002; 168 : 1730-7.
61. Chen P, Li J, Barnes J, Kokkonen GC, Lee JC, Liu Y. Restraint of proinflammatory cytokine biosynthesis by Mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. *J Immunol* 2002; 169 : 6408-16.



62. Sun JB, Holmgren J, Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. *Proc Natl Acad Sci USA* 1994; *91* : 10795-9.
63. Sun JB, Rask C, Olsson T, Holmgren J, Czerkinsky C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. *Proc Natl Acad Sci USA* 1996; *93* : 7196-201.
64. Bergerot I, Ploix C, Petersen J, Moulin V, Rask C, Fabien N, *et al.* A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. *Proc Natl Acad Sci USA* 1997; *94* : 4610-4.
65. Sobel DO, Yankelevich B, Goyal D, Nelson D, Mazumder A. The B-subunit of cholera toxin induces immunoregulatory cells and prevents diabetes in the NOD mouse. *Diabetes* 1998; *47* : 186-91.
66. Sun J-B, Raghavan S, Sjöling A, Lundin S, Holmgren J. Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3<sup>+</sup>CD25<sup>+</sup> and Foxp3<sup>+</sup>CD25<sup>-</sup>CD4<sup>+</sup> regulatory T cells. *J Immunol* 2006; *177* : 7634-44.
67. Phipps PA, Stanford MR, Sun J-B, Xiao B-G, Holmgren J, Shinnick T, *et al.* Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit. *Eur J Immunol* 2003; *33* : 224-32.
68. Stanford M, Whittall T, Bergmeier LA, Lindblad M, Lundin S, Shinnick T, *et al.* Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease. *Clin Exp Immunol* 2004; *137* : 201-8.
69. Stål P, Befrits R, Rönnblom A, Danielsson A, Suhr O, Stahlberg D, *et al.* Clinical trial: safety and short-term efficacy of recombinant cholera toxin B-subunit (rCTB) in the treatment of active Crohn's disease. *Aliment Pharmacol Ther* 2010; *31* : 387-95.

*Reprint requests:* Prof. N.K. Ganguly, Distinguished Biotechnology Research Professor & Advisor, Translational Health Science and Technology Institute, National Institute of Immunology, Aruna Asaf Ali Marg, J.N.U. Complex, New Delhi 110 067, India  
e-mail: nkganguly@nii.res.in